GO:1990697 protein depalmitoleylation: Genes & Methods

Protein depalmitoleylation (GO:1990697) is a post-translational modification process that removes a palmitoleyl group, a 16-carbon monounsaturated fatty acid (C16:1), from a lipoprotein. This process is part of the dynamic regulation of protein lipidation, which controls protein localization, stability, and function. While palmitoylation (addition of palmitate, C16:0) is well studied, depalmitoleylation specifically targets palmitoleate and is less understood. The reaction is catalyzed by thioesterases that hydrolyze the thioester bond between the fatty acid and cysteine residues on target proteins. Protein S, a key anticoagulant, is a prominent example of a protein that undergoes palmitoleylation and depalmitoleylation, and these modifications affect its secretion and activity [3, 8]. Researchers study protein depalmitoleylation to understand how cells regulate lipid-modified proteins in processes such as blood coagulation, signal transduction, and membrane trafficking. Dysregulation of this process has been implicated in thrombotic disorders, including those associated with COVID-19, where protein S levels and function are altered. Genetic modifiers of protein S plasma levels further highlight the clinical importance of this pathway. Given the emerging role of protein depalmitoleylation in health and disease, there is growing interest in identifying the enzymes and regulatory mechanisms involved. This article provides a comprehensive overview of GO:1990697, covering its definition, mechanism, key genes, disease associations, and research methods, with a focus on CRISPR-based approaches for functional studies.

Protein depalmitoleylation is the biological process that removes a palmitoleyl group, a 16-carbon monounsaturated fatty acid (C16:1), from a lipoprotein. This enzymatic reaction reverses the covalent attachment of palmitoleate to cysteine residues via a thioester bond, thereby modulating the hydrophobicity and membrane affinity of the target protein. The process is distinct from depalmitoylation, which removes the saturated fatty acid palmitate (C16:0). Depalmitoleylation is catalyzed by thioesterases, such as acyl-protein thioesterases, and plays a role in regulating protein trafficking, stability, and function [3, 8].

Protein depalmitoleylation is important because it dynamically regulates the lipid modification state of proteins, which in turn controls their subcellular localization, stability, and activity. This process is critical for the function of proteins involved in blood coagulation, such as protein S, where palmitoleylation and depalmitoleylation influence its anticoagulant activity [3, 8]. Dysregulation of protein S and its modifications has been linked to thrombotic disorders, including deep vein thrombosis and COVID-19-associated coagulopathy [1, 5]. Understanding protein depalmitoleylation may therefore provide insights into the pathogenesis of these conditions and reveal new therapeutic targets.

The following genes and proteins are involved in or regulated by protein depalmitoleylation, based on published literature.

Protein depalmitoleylation is regulated by the availability of palmitoleoyl-CoA, the activity and localization of thioesterases, and the presence of specific substrate proteins. The process can be influenced by cellular signaling pathways that control lipid metabolism and enzyme activity. For example, growth factor signaling may alter the expression or activity of acyl-protein thioesterases, thereby affecting depalmitoleylation rates. Additionally, the balance between palmitoleylation and depalmitoleylation is maintained by opposing enzymes: palmitoyl acyltransferases (ZDHHC family) add the fatty acid, while thioesterases remove it. Dysregulation of this balance can lead to disease, as seen in protein S deficiency and thrombosis [2, 5].

Protein S deficiency is a well-established risk factor for venous thrombosis. Protein S undergoes palmitoleylation and depalmitoleylation, and these modifications are critical for its secretion and anticoagulant function. Mutations in PROS1 that impair protein S function or processing can lead to deficiency and increased thrombotic risk. Understanding how depalmitoleylation regulates protein S activity may provide new insights into thrombosis pathogenesis and treatment.

Dysregulation of protein S has been observed in COVID-19 patients, contributing to coagulopathy. The virus may affect protein S levels or function, potentially through alterations in post-translational modifications such as depalmitoleylation. This highlights the importance of understanding protein depalmitoleylation in the context of infectious diseases and inflammation.

Genetic modifiers can influence plasma levels of protein S, affecting disease susceptibility. Variations in genes involved in protein S synthesis, secretion, or modification, including those related to depalmitoleylation, may contribute to interindividual differences in protein S levels. Identifying these modifiers could improve risk assessment for thrombotic disorders.

In vitro assays using recombinant thioesterases and palmitoleylated substrate proteins can directly measure depalmitoleylation activity. These assays typically use radiolabeled or fluorescently labeled palmitoleate and monitor its release via chromatography or fluorescence polarization. Such methods are essential for identifying enzymes and characterizing their kinetics.

Mass spectrometry can identify and quantify palmitoleylated proteins and their modification sites. By comparing wild-type and knockout cells, researchers can determine the specific substrates of depalmitoleylation enzymes. This approach is powerful for global profiling of lipid modifications.

CRISPR-Cas9 allows for the generation of knockout, point mutation, and knock-in cell models to study protein depalmitoleylation. For example, knocking out LYPLA1 or PROS1 can reveal their roles in the process. Point mutations can be introduced to ablate specific cysteine residues that are palmitoleylated.

Fluorescence microscopy of tagged proteins (e.g., GFP-tagged protein S) can visualize changes in localization upon depalmitoleylation. This method helps link the modification to protein trafficking and function.

Researchers studying protein depalmitoleylation-related genes often need to determine whether a candidate gene is causally involved in the process, and CRISPR-based models provide a robust way to test this. By generating knockout, point mutation, knock-in, and overexpression cell lines, scientists can dissect the molecular mechanisms and disease relevance of depalmitoleylation.

Protein depalmitoleylation (GO:1990697) is a specialized post-translational modification that removes palmitoleate from proteins, thereby regulating their function and localization. Its role in protein S biology and thrombosis underscores its clinical importance [2, 8]. Advances in CRISPR-based models and biochemical assays are poised to uncover the enzymes and pathways involved, offering new opportunities for therapeutic intervention. Continued research into this process will enhance our understanding of coagulation, immunity, and beyond.